Key Points
- Insider sale: Ramiro Ribeiro sold 2,437 shares on April 17 at an average price of $15.00, totaling $36,555, as disclosed in an SEC filing.
- Weak recent results: Eyepoint reported Q results of ($0.81) EPS vs. ($0.78) expected and revenue of $0.62M vs. $1.01M expected, carries a negative PE and large negative margins, and trades in a 52‑week range of $5.30–$19.11 with a market cap around $1.26B.
- Institutional and analyst view: Institutional investors own about 99.41% of the stock with large positions from firms like Janus Henderson, Suvretta and Federated Hermes, and analysts have a consensus "Buy" rating with an average target of $32.20.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Eyepoint Pharmaceuticals Stock Performance
Shares of NASDAQ EYPT opened at $15.07 on Tuesday. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $5.30 and a fifty-two week high of $19.11. The firm has a market capitalization of $1.26 billion, a PE ratio of -4.77 and a beta of 1.89. The stock's 50-day simple moving average is $14.51 and its 200-day simple moving average is $14.57.
Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%.The business had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.01 million. On average, sell-side analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -3.01 earnings per share for the current fiscal year.
Institutional Trading of Eyepoint Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of EYPT. Janus Henderson Group PLC acquired a new position in Eyepoint Pharmaceuticals in the 4th quarter valued at about $53,658,000. Paradigm Biocapital Advisors LP acquired a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $28,556,000. Orbimed Advisors LLC acquired a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $25,575,000. Suvretta Capital Management LLC grew its position in Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company's stock valued at $143,012,000 after buying an additional 1,634,970 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in Eyepoint Pharmaceuticals by 36.3% in the 4th quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company's stock valued at $109,938,000 after buying an additional 1,601,101 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company's stock.
Analysts Set New Price Targets
A number of research analysts recently commented on EYPT shares. HC Wainwright increased their target price on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 5th. Chardan Capital upped their target price on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Citigroup upped their target price on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Monday, March 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $32.20.
Read Our Latest Report on Eyepoint Pharmaceuticals
Eyepoint Pharmaceuticals Company Profile
(
Get Free Report)
Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.
Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
